BRWA
PTCT icon

B. Riley Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

B. Riley Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,697
Closed -$392K – 842
2019
Q2 		$392K Buy
+8,697
New +$343K 0.04% 466

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

B. Riley Wealth Advisors's PTCT Position: Q3 2019 in Review

B. Riley Wealth Advisors sold out of PTC Therapeutics (PTCT) in Q3 2019, closing a stake of 8,697 shares — an estimated $392K sold.

B. Riley Wealth Advisors first reported a position in PTCT in Q2 2019 and held it in 1 quarter. The position peaked at $392K in Q2 2019. 184 funds tracked by Wall St. Rank hold PTCT as of Q3 2019.

  • B. Riley Wealth Advisors reported no remaining PTC Therapeutics position as of Q3 2019 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 8,697 PTC Therapeutics shares in Q3 2019, an estimated $392K.
  • B. Riley Wealth Advisors first reported a position in PTC Therapeutics in Q2 2019 and held it in 1 quarter.
  • B. Riley Wealth Advisors's PTC Therapeutics position peaked at $392K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2019.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.